This article is more than 5 years old. Information may no longer be current.
Santen looking for ‘more direct presence’ in United States
Click Here to Manage Email Alerts
WAIKOLOA, Hawaii — Santen Inc. is committed to establishing a larger presence in the United States, according to a company official.
Ted Danse, the vice president of strategic marketing and business development for Santen Inc., said the company is “committed to becoming more of a global player than it is right now.”
Santen Inc., based in the San Francisco area, is a wholly owned subsidiary of the Japanese company Santen Pharmaceutical Co. Ltd.
Mr. Danse, who recently joined the company, said Santen is “looking for more of a direct presence in the U.S.”
He said the company is developing products for the treatment of dry eye, glaucoma and retinal disease, including an angiotensin-2 inhibitor.
Santen manufactures the anti-infectives Quixin (levofloxacin 0.5%) and Iquix (levofloxacin 1.5%), the glaucoma medication Betimol (timolol) and the allergy drug Alamast (pemirolast potassium). Those drugs are marketed and distributed by Vistakon through a joint agreement with Johnson & Johnson.
In an interview with Ocular Surgery News at Hawaii 2005, The Royal Hawaiian Eye Meeting, Mr. Danse said Santen is looking to identify other partnerships with other companies, and will “take risks where appropriate.”
“We’re not going to have closed minds,” he said.